Get to know our clinical trials
Clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of AFM24 in combination with atezolizumab in patients with selected EGFR-expressing advanced/metastatic cancer.
THE OBJECTIVE OF THE STUDY IS TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) AND/OR SELECT ONE OR MORE RECOMMENDED DOSES IN PHASE 2 (DRF2) OF AFM24 IN COMBINATION WITH ATEZOLIZUMAB.
- PHASE 1/2A, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF AFM24 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED EGFR-EXPRESSING ADVANCED/METASTATIC CANCER. IMMUNOTHERAPY.
- Code EudraCT: 2021-000707-20
- Protocol number: AFM24-102
- Promoter: Affimed GmbH
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.